Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study - Takeaways - MDSpire

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

  • By

  • Carlyn Rose Tan

  • Sireesha Asoori

  • Chiung-Yu Huang

  • Larissa Brunaldi

  • Rakesh Popat

  • Efstathios Kastritis

  • Joaquin Martinez-Lopez

  • Radhika Bansal

  • Andre De Menezes Silva Corraes

  • Saurabh Chhabra

  • Ricardo Parrondo

  • Sikander Ailawadhi

  • Despina Fotiou

  • Meletios A. Dimopoulos

  • Kwee Yong

  • Catriona Mactier

  • Chris Lau

  • Magdalena Corona

  • Adolfo Jesús Sáez Marin

  • Hira Mian

  • Brian GM. Durie

  • Saad Z. Usmani

  • Thomas G. Martin

  • Yi Lin

  • April 3, 2025

  • 0 min

Share

  • 1

    Teclistamab is the first approved BCMAxCD3 bispecific antibody for triple-class-exposed patients with relapsed/refractory multiple myeloma.

  • 2

    In the MajesTEC-1 study, teclistamab showed an overall response rate of 63% and a complete response rate of 46.1% after 30.4 months.

  • 3

    Real-world data from 210 patients indicated an overall response rate of 67%, with 34% achieving very good partial response.

  • 4

    Teclistamab is associated with significant side effects, including cytokine release syndrome in 72.1% of patients and high rates of infection.

  • 5

    71% of patients in the real-world cohort would not have met eligibility criteria from the MajesTEC-1 study, highlighting treatment challenges.

Original Source(s)

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

  • by Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, Larissa Brunaldi, Rakesh Popat, Efstathios Kastritis, Joaquin Martinez-Lopez, Radhika Bansal, Andre De Menezes Silva Corraes, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Despina Fotiou, Meletios A. Dimopoulos, Kwee Yong, Catriona Mactier, Chris Lau, Magdalena Corona, Adolfo Jesús Sáez Marin, Hira Mian, Brian GM. Durie, Saad Z. Usmani, Thomas G. Martin, Yi Lin

  • April 3, 2025

Related Content

Patient Awareness, Attitudes, and Preventive Practices Related to Venous Thromboembolism in Multiple Myeloma: A Cross-Sectional Analysis

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside

Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma